<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Stromal cells from a child with constitutional <z:mp ids='MP_0004027'>trisomy</z:mp> 8 who developed <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) were found to produce abnormal levels of various cytokines, including VEGF, and supported the growth of leukemic cells in co-culture assays </plain></SENT>
<SENT sid="1" pm="."><plain>This study shows that the geldanamycin derivative 17-AAG effectively reduces the VEGF expression by <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> stromal cells </plain></SENT>
<SENT sid="2" pm="."><plain>In co-culture experiments this agent also blocks the ability of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> stromal cells to stimulate the growth of leukemic cells </plain></SENT>
<SENT sid="3" pm="."><plain>These data provide important initial evidence for the effect of 17-AAG on the marrow microenvironment and its potential use in the treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
</text></document>